Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Under the patronage of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the United Arab Emirates, His Highness ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit. A new study found that a drug in the same class ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Ozempic works by mimicking the hormone GLP-1, which suppresses hunger and regulates blood sugar levels. All semaglutide ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.